JP5934229B2 - 眼血管疾患の処置のための投与計画 - Google Patents

眼血管疾患の処置のための投与計画 Download PDF

Info

Publication number
JP5934229B2
JP5934229B2 JP2013535408A JP2013535408A JP5934229B2 JP 5934229 B2 JP5934229 B2 JP 5934229B2 JP 2013535408 A JP2013535408 A JP 2013535408A JP 2013535408 A JP2013535408 A JP 2013535408A JP 5934229 B2 JP5934229 B2 JP 5934229B2
Authority
JP
Japan
Prior art keywords
days
methyl
vegf
inhibitor
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013535408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540791A (ja
JP2013540791A5 (https=
Inventor
ミッチェル・ブリゲル
ペーター・エント
ビナヤク・ホサグラハラ
ブルース・ジャッフェ
エリック・メレディス
ロナルド・ニュートン
スティーブン・プア
ユービン・チウ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013540791A publication Critical patent/JP2013540791A/ja
Publication of JP2013540791A5 publication Critical patent/JP2013540791A5/ja
Application granted granted Critical
Publication of JP5934229B2 publication Critical patent/JP5934229B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013535408A 2010-10-27 2011-10-25 眼血管疾患の処置のための投与計画 Expired - Fee Related JP5934229B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40721810P 2010-10-27 2010-10-27
US61/407,218 2010-10-27
PCT/EP2011/068682 WO2012055884A1 (en) 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease

Publications (3)

Publication Number Publication Date
JP2013540791A JP2013540791A (ja) 2013-11-07
JP2013540791A5 JP2013540791A5 (https=) 2014-12-04
JP5934229B2 true JP5934229B2 (ja) 2016-06-15

Family

ID=44913251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535408A Expired - Fee Related JP5934229B2 (ja) 2010-10-27 2011-10-25 眼血管疾患の処置のための投与計画

Country Status (12)

Country Link
US (1) US20130197016A1 (https=)
EP (1) EP2632458B1 (https=)
JP (1) JP5934229B2 (https=)
KR (1) KR20140008303A (https=)
CN (1) CN103167873A (https=)
AU (1) AU2011322597B2 (https=)
BR (1) BR112013009701A2 (https=)
CA (1) CA2814439A1 (https=)
EA (1) EA022873B1 (https=)
ES (1) ES2547145T3 (https=)
MX (1) MX2013004782A (https=)
WO (1) WO2012055884A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
JP6669499B2 (ja) * 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
US10174006B2 (en) * 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
CN105917270A (zh) 2013-11-15 2016-08-31 视觉力学有限责任公司 具有亲水层的接触透镜
JPWO2015147204A1 (ja) * 2014-03-27 2017-04-13 国立大学法人京都大学 血管新生増殖因子を阻害する医薬組成物
JP6774947B2 (ja) 2014-12-09 2020-10-28 タンジブル サイエンス インコーポレイテッド 生体適合性層を有する医療デバイスコーティング
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
WO2021067823A2 (en) * 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1652847B1 (en) 2001-04-27 2008-05-28 Kirin Pharma Kabushiki Kaisha Quinoline and quinazoline derivatives for the treatment of tumors
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
PL1954281T3 (pl) 2005-11-29 2011-07-29 Novartis Ag Sposób leczenia raka
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Also Published As

Publication number Publication date
ES2547145T3 (es) 2015-10-02
JP2013540791A (ja) 2013-11-07
KR20140008303A (ko) 2014-01-21
CA2814439A1 (en) 2012-05-03
EP2632458B1 (en) 2015-08-12
EA022873B1 (ru) 2016-03-31
US20130197016A1 (en) 2013-08-01
BR112013009701A2 (pt) 2016-07-19
AU2011322597A1 (en) 2013-05-02
WO2012055884A1 (en) 2012-05-03
MX2013004782A (es) 2013-06-03
AU2011322597B2 (en) 2015-09-10
EP2632458A1 (en) 2013-09-04
EA201390618A1 (ru) 2013-08-30
CN103167873A (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
JP5934229B2 (ja) 眼血管疾患の処置のための投与計画
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
US11951103B2 (en) Pharmaceutical composition
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
CN102105167A (zh) 轴性近视的预防或治疗剂
JPWO2015060208A1 (ja) 眼疾患の治療剤又は予防剤
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
US20140302009A1 (en) Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability
US20230025836A1 (en) Eye drop composition for preventing or treating eye disease
JP2011144111A (ja) 軸性近視の予防または治療剤
KR20150051493A (ko) 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관신생 관련 질환의 예방 또는 치료용 약학적 조성물
HK40069641A (en) Compositions and methods for treating pterygium
JP2014193854A (ja) テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤
Croasdell Association for Research in Vision and Ophthalmology (ARVO)-2018 Annual Meeting. Honolulu, Hawaii, USA-April 29-May 3, 2018
HK40035073A (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
HK1256602B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140725

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140725

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160506

R150 Certificate of patent or registration of utility model

Ref document number: 5934229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees